Synthesis and Antihypertensive Screening of New Derivatives of Quinazolines Linked with Isoxazole
Table 1
Dose establishment for the screening of antihypertensive activity.
Compd.
Average systolic blood pressure (mmHg) with different oral doses (mg/day) at different time (days)
MAP (Mean ± SEM)
% Reduction in MAP
% Inhibition In SBP
0
1
2
3
4
5
6
7
8
9
10
1
11.09
04.68
2
31.00
16.83
3
27.09
13.91
4
19.45
10.25
5
17.90
09.74
6
19.63
08.85
7
24.36
12.82
8
19.54
10.71
9
21.00
10.82
10
17.36
09.23
11
16.81
08.76
12
17.45
08.76
13
25.09
13.33
14
17.18
08.76
15
25.54
12.88
16
19.00
10.25
17
18.00
09.27
18
27.54
13.02
19
25.90
13.84
20
21.36
11.73
21
23.81
12.37
22
20.54
10.76
23
28.63
14.43
24
40.54
19.79
25
17.27
09.23
26
18.27
10.20
27
25.00
12.88
28
23.81
12.82
29
21.18
10.82
30
19.63
08.85
PZN
37.45
18.65
TC
—
CT
—
All values were expressed as Mean ± SEM ); each group comprised 6 animals (i.e., ); MAP (mean arterial pressure); SBP (systolic blood pressure). Prazosin (PZN), toxic control (TC) group was compared with control (CT) group. All the treatment groups were compared with toxic control group and was considered to be significant. , , and nonsignificant. % inhibition in SBP = initial SBP−MAP/initial SBP .
